Dry powder inhalers (DPIs) are increasingly replacing metered dose inhalers in elderly chronic obstructive pulmonary disease (COPD) patients. However, most DPIs are dependent on inspiratory flow, which is compromised by the ageing process itself.
Using the in-check dial method, the present study compared peak inspiratory flow (PIF) rates in 26 elderly COPD patients and 14 matched control subjects, at a pre-set resistance level of the Aeroliser®, Diskus® and Turbuhaler® inhalers.
It was found that the PIF measured by the in-check method positively correlated with the PIF derived from spirometry, forced vital capacity and maximal inspiratory pressure, while a negative, but significant, correlation was observed with age. PIF derived from spirometry and age were independent variables which determined PIF across the device, whereas the presence or absence of COPD was not related. When comparing elderly COPD patients with matched elderly controls no difference could be found in PIF at the different resistances. However, an important number of patients did not reach the recommended flow rate, especially when using the Turbuhaler® (30%).
In conclusion, the present study demonstrates that, in elderly patients, the ability to generate sufficient inspiratory flow across a dry powder inhaler is compromised, irrespective of the presence of chronic obstructive pulmonary disease.
Inhaled medication plays an important role in the treatment of chronic obstructive pulmonary disease (COPD), with dry powder inhalers (DPIs) increasingly replacing metered dose inhalers (MDIs). DPIs are interesting as they do not require the need for coordinate actuation of the MDI device with inhalation or the use of a large spacer device 1–3. Several DPIs are available for the administration of inhaled corticosteroids, as well as bronchodilators, with each of them corresponding to a different type of inhaler (e.g. Diskus®, Turbuhaler®, Aeroliser®, etc.). During the inspiratory effort the patient generates a pressure drop with a consequent airflow across the DPI. This inspiratory flow has to be high enough to disaggregate and adequately disperse the drug powder into an aerosol cloud of drug particles and to guarantee an optimal deposition of the medication in the lung 3–5. Such peak inspiratory flows (PIFs) are not only dependent on a patient's inhalation effort but also on the internal resistance of the device 6–8.
It has been shown that optimal deposition of medication with DPIs is not achieved in some patients with low inspiratory flow rates, such as children 9, 10, or patients with asthma or COPD, especially during acute exacerbations 11–13. In such conditions the use of a DPI with low internal resistance has been suggested, ensuring an optimal deposition despite the lower flow rate 12, 14. In addition, many clinicians are nowadays confronted with an important number of COPD patients who are aged >70 yrs. In this subpopulation, DPIs are often preferred to MDIs as the coordination between device and inhalation becomes increasingly difficult with age 1, 15, 16. However, elderly subjects are known to have reduced respiratory muscle strength and decreased PIF due to the ageing process itself, which may jeopardise the adequate use of DPI independently of COPD 17.
One recent publication reports on decreased inspiratory flow rates at high levels of resistance in elderly COPD patients 18. In view of this perspective, the present authors performed a study in which PIF was measured at different levels of resistance in elderly COPD patients and then compared with matched control subjects. It was also evaluated whether elderly COPD patients could generate the required PIF to overcome the internal resistance of currently available DPIs.
MATERIALS AND METHODS
The study comprised of 40 male subjects. The youngest subject was 70 yrs of age and the oldest 87 yrs of age. The 26 elderly patients with COPD were recruited from the outpatient clinic of pulmonary medicine of the Algemeen Ziekenhuis Sint Maarten (Duffel, Belgium). A diagnosis of COPD was based on a smoking history of ≥10 pack-yrs and the Global Initiative of Chronic Lung Disease (GOLD) definition of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <70% predicted. The elderly control group consisted of 14 subjects without COPD, who were community dwelling and were recruited from the records of local general practitioners. These subjects completed a questionnaire and underwent a clinical examination that proved they were in good general health, were not taking pulmonary medication and had no pulmonary complaint or disease. Ethics committee (A.Z. St-Maarten) approval was obtained and all participants gave informed consent.
Pulmonary function measurements
Pulmonary function variables were measured according to the European Respiratory Society guidelines for pulmonary function testing and the results were expressed as a percentage of the predicted normal values of Quanjer et al. 19. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were measured according to a modification of the method of Black and Hyatt 20. MIP was measured from residual volume and MEPwas measured as close as possible to total lung capacity. The highest pressure sustained for 1 s against a closed mouthpiece was defined as the maximum. COPD patients were asked to withhold long-acting β2-agonist use for 12 h prior to the lung function tests. as the corresponding devices were the subject of the present study. All measurements were performed between 09:00 and 11:00 h. All manoeuvres were executed and encouraged by trained technicians under the supervision of medical staff.
In-check inhaler assessment
PIF related to different resistances was measured using the In-Check Inhaler Assessment Kit (Clement Clarke International Ltd, Harlow, UK) 6, 14, 21. This device was used in order to compare PIF rates over three different DPIs commonly used in Belgium for the administration of long-acting β2-agonists. PIF device was defined as the maximal inspiratory flow (MIF) over the device without additional resistance and compared with the MIF over the device at a given resistance of 0.1 cmH2O·L−1·min−1 (Turbuhaler®), 0.086 cmH2O·L−1·min−1 (Diskus®) and 0.055 cmH2O·L−1·min−1 (Aeroliser®). The highest value of the three attempts was recorded. PIFs >60 L·min−1 are generally believed to be the optimal flows for most of the devices, while PIFs <30 L·min−1 are accepted to be insufficient for generating any effect 6, 22–30. As there is still discussion about the effectiveness of PIFs ranging 30–60 L·min−1 14, 31, 32, an arbitrary cut-off at a PIF of 45 L·min−1 was made in order to distinguish therapeutic flows from subtherapeutic levels.
Data are expressed as mean±sd. Subjects' characteristics and lung function tests were compared using an unpaired t-test. Correlations between different variables were expressed by Pearson correlation coefficients. A stepwise multiple regression was performed to investigate independent predictors of the PIF through the device at different resistances. Potentially important variables were FVC, FEV1, FVC % pred, FEV1 % pred, PIF, age, inspiratory muscle force, COPD diagnosis and severity of COPD. These variables were all included in the regression models in which the 0.05 significance level was retained for final entry. According to the GOLD classification, severity of COPD was introduced as a dichotomous variable, differentiating severe and very severe COPD (FEV1 <50% pred) from moderate and mild COPD. PIFs at different resistances were compared via one-way ANOVA. To compare PIFs at different resistances between COPD patients and elderly controls, a two-sided ANOVA analysis was carried out. A value of p<0.05 was considered significant.
In total, 26 COPD patients and 14 controls were included the study. Table 1⇓ demonstrates the baseline characteristics of both groups. In order to investigate which parameters may determine the PIF as assessed by the in-check dial, a correlation analysis was performed in the whole study population (n = 40) as well as in the COPD subgroup (n = 26; fig. 1⇓). In both groups, PIF measured by the in-check method at zero resistance (PIF device) correlated best with the PIF measured during spirometry (whole group: r = 0.51; COPD: r = 0.58; p<0.005). In the total study group, the PIF device also significantly (p<0.005) correlated with age (r = -0.5), FVC (r = 0.46), MIP (r = 0.42), MEP (r = 0.5), peak expiratory flow (r = 0.46) and height (r = 0.4; data not shown). No statistically significant correlation could be found with body mass index, Tiffeneau index, FEV1, FEV1 % pred and FVC % pred. A stepwise multiple regression was performed on all 40 participants to study independent predictors of the PIF device. It was found that spirometric PIF (partial R2: 0.25, p = 0.0008) and age (partial R2: 0.12, p = 0.014) independently contributed to the variance of PIF device (R2: 0.37, p<0.001). The other variables could not be retained. Stepwise multiple regression for the PIF over the Aeroliser®, Diskus® and Turbuhaler® could only withhold PIF measured by spirometry as an independent predictor (Aeroliser®: R2 = 0.45, p<0.001; Diskus®: R2 = 0.42, p<0.0001; Turbuhaler®: R2 = 0.39, p<0.001; fig 1⇓).
The in-check device was pre-set at resistances that corresponded to the airflow resistances of the Aeroliser®, Diskus® and Turbuhaler®. As expected, in COPD patients as well as in the elderly control population, the PIF rates measured by the in-check method were significantly lower with increasing resistances (one-way ANOVA and Bonferonni multiple comparison test, p<0.01; data not shown). When COPD patients were compared with elderly controls, no statistically significant difference could be observed (two-way ANOVA, p = 0.09) in the PIFs between both groups at any given resistance (fig. 2⇓).
PIFs measured by the in-check method were subsequently divided into four different categories: flows >60 L·min−1; flows 45–60 L·min−1; flows 30–45 L·min−1; and flows <30 L·min−1. An arbitrary cut-off point was selected at 45 L·min−1 in order to distinguish therapeutic flows from subtherapeutic levels. Therapeutic flows >45 L·min−1 were obtained in 87.5% (n = 35), 80% (n = 32) and 70% (n = 28) of cases for the Aeroliser®, Diskus® and Turbuhaler®, respectively. When comparing the flow rates to the previously described minimal flow rate of 30 L·min−1, 12.5% (n = 5) of the Turbuhaler® users were unable to generate the minimal required flow, whereas all patients (n = 40) could attain this minimal flow when using the Aeroliser® or Diskus®. A statistically significant difference between COPD patients and elderly controls could not be observed on any of the different categories (Fisher-exact test, p>0.05; fig. 3⇓).
The present study examines the PIF that can be generated over different DPIs in an elderly patient population by using the in-check method. It was demonstrated that the PIF over a DPI positively correlated with the spirometric PIF, FVC and MIP, while a negative, but significant, correlation could be observed with age. Stepwise multiple regression analysis could only retain spirometric PIF as an independent predictor for explaining the variance of PIF across the device at any given resistance. The presence and severity of COPD did not contribute to the present model. When the elderly COPD patients and matched healthy controls were compared, no difference was observed in the subjects’ ability to achieve acceptable flows over the different DPIs tested. Nevertheless, an important number of patients were unable to reach the PIF recommended for an optimal therapeutic effect.
The PIF over a DPI depends on the MIPa patient can generate, but also on the resistance attributable to the device and to the patients’ airways 8. The current data are consistent with previous reports in asthmatics and COPD patients 5, 33, 34. In these publications, it was demonstrated that lung function variables predictive for PIF across a DPI were MIP, spirometric PIF and inspiratory capacity, whereas FEV1, as an expression of the severity of illness, did not correlate with the MIF rate over a device. Similar correlations were found in the present study in addition to a negative correlation between PIF device and age, which could be expected given the age dependency of PIF in prediction equations. Therefore, it is very likely that in an elderly population the optimal use of DPIs decreases with age for reasons of reduced inspiratory muscle force, lower spirometric PIF 17 and the fact that with age the correct use of a DPI becomes more difficult 15, 16.
The present data could not demonstrate a significant difference between the elderly COPD population and the healthy control group when looking at inspiratory flows across the different devices. As COPD is, above all, an expiratory disease that does not directly affect inspiratory flow rates, this finding is not surprising and has already been previously reported 5, 34. In a younger COPD population (mean age 56 yrs) it has been demonstrated that all patients were able to generate PIFs >50 L·min−1 against several resistances 34. The authors consequently concluded that each COPD patient could benefit from all the different types of DPIs available. In the elderly study population, however, flow rates <45 L·min−1 were present in 12.5% (n = 5), 20% (n = 8) and in 30% (n = 12) of cases for the Aeroliser®, Diskus® and Turbuhaler®, respectively. This is consistent with the findings of Nsour et al. 16, who described in 23 (31%) out of 74 COPD patients (mean age 79 yrs) PIFs <40 L·min−1 when using the Turbuhaler®. The fact that Dewar et al. 32 found subtherapeutic flows <40 L·min−1 over the Turbohaler® in only 17 (17%) out of 100 COPD patients might be explained by the lower mean age (69 yrs) of their population. As in the current study, 15 younger patients (mean age 36 yrs) were all able to achieve PIFs >60 L·min−1 when using the same device and protocol (data not shown). The present authors believe that age, much more than COPD severity, should be taken into account when prescribing DPIs for stable COPD in an elderly population.
Most authors agree on the fact that in the case of reduced inspiratory flow, a low-resistance DPI that is relatively insensitive to changes in airflow will be more beneficial. Manufacturers should, therefore, be encouraged to label products with its specific resistance and the dose emitted at different flow rates 14. The present data demonstrate that 30% of the elderly population were not able to reach the arbitrary cut-off flow of 45 L·min−1 when using a Turbuhaler®, while only 20 and 12.5% of the population had similar problems with the Diskus® and Aeroliser®, respectively. Turbuhaler® and Aeroliser® are less effective at a PIF <60 L·min−1, whereas the Diskus® seems to have an equal effect at a PIF 30–60 L·min−1 6, 22–30. This could mean that, in contrast to the Diskus®, the number of patients with subtherapeutic flows over the Aeroliser® or Turbuhaler® is even underestimated. Whether this suboptimal flow also results in a different clinical outcome in terms of symptom relief, reduction of exacerbations and lower mortality is currently not known. This should be investigated further in future studies.
In conclusion, the present study demonstrates that in elderly patients the ability to generate sufficient inspiratory flow across a dry powder inhaler is compromised, irrespective of the presence of chronic obstructive pulmonary disease. This is an important finding as elderly people are generally encouraged to use a dry powder inhaler instead of metered dose inhalers, due to its easier application. Ideally, the choice for the most appropriate dry powder inhaler in elderly patients should, therefore, depend on the objective measurement of peak inspiratory flow against a certain resistance. Alternatively, the direct choice of a low-resistance dry powder inhaler, which is relative insensitive to changes in peak inspiratory flow at lower flow levels, might be beneficial in situations such as exacerbations characterised by a further reduction of inspiratory flow 12, 21, 35.
- Received March 1, 2007.
- Accepted September 11, 2007.
- © ERS Journals Ltd